0000000000083070

AUTHOR

P. K. E. Trinder

showing 12 related works from this author

Interleukin-7

2003

This chapter discusses interleukin (IL)-7, which is an important lymphopoietin that plays a critical role in both B- and T-cell development. IL-7 promotes expansion of T lymphocytes exhibiting antigen-specific reactivity. IL-7 may be implemented to promote strong and effective immune responses against tumor cells, or directed against microbial or viral infections. It may also be useful in reconstituting an effective, and functional immune system after bone marrow transplantation, or helping to design novel strategies for immune reconstitution in patients with cancer or with HIV infection. IL-7 serves as the major growth and differentiation factor for both thymic and extrathymic development …

Immune systemIn vivoImmunologymedicineLymphokineCancerInterleukinIn patientBiologymedicine.diseaseAcquired immune systemIn vitro
researchProduct

Evidence for auto-reactivity against the collectins, SP-A and MBL, in rheumatoid arthritis synovial fluids: Lack of cross-reactivity with C1q or type…

1997

ChemistryRheumatoid arthritisImmunologyImmunologymedicineType II collagenImmunology and AllergyCollectinReactivity (chemistry)medicine.disease_causemedicine.diseaseCross-reactivityImmunology Letters
researchProduct

Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer.

1998

Although not structurally related, the pleiotropic cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15) share a variety of biological functions including stimulation and maintenance of cellular immune responses. Cytokines, such as IL-7 or IL-15, elaborated by cells in situ, e.g. cancer cells, may be involved in shaping the quality of anti-tumor directed immune responses. We have analysed the constitutive and IFN-gamma-inducible expression of IL-15 or IL-7 mRNA, protein expression, and protein secretion in human tumor cell lines of distinct origin. IL-15 mRNA expression was detected in renal cell carcinoma (RCC), small cell lung carcinoma (SCLC), glioblastoma, neuroblastoma, mesotheliom…

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentCellBiologyInterferon-gammaInternal medicinemedicineHumansSecretionRNA MessengerCarcinoma Renal CellInterleukin-15OncogeneInterleukin-7CancerCell cyclemedicine.diseaseKidney NeoplasmsEndocrinologymedicine.anatomical_structureCytokineOncologyGene Expression RegulationInterleukin 15Cancer cellCancer researchColorectal NeoplasmsInternational journal of oncology
researchProduct

Functional Definition of a B Cell Epitope, KGEQGEPGA, on C1q the Fc-Binding Subunit of the First Component of Complement

1999

A synthetic peptide representing the C1q epitope KGEQGEPGA has been shown to suppress or delay the onset of CII-induced arthritis when applied intravenously (i.v.) prior to an intradermal (i.d.) challenge, in a mouse model; the phenomenon being associated with the development of immunoglobulin (Ig)M antibodies specific for the KGEQGEPGA epitope. Here we show that this amino acid sequence provides an immunodominant B cell epitope that is recognised by autoantibodies present in the sera of patients with chronic inflammatory diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, two diseases associated with an immune response to C1q. The peptide's ability to produce pept…

Linear epitopebiologyImmunologyGeneral MedicineMolecular biologyEpitopeComplement systemClassical complement pathwaymedicine.anatomical_structureImmunoglobulin class switchingImmunologybiology.proteinmedicineAntibodyPeptide sequenceB cellScandinavian Journal of Immunology
researchProduct

Autoreactivity to mouse C1q in a murine model of SLE.

1995

A large proportion of systemic lupus erythematosus (SLE) patients develop glomerulonephritis, coincident with the appearance of autoantibodies to C1q, the Fc-recognizing collagen-like subcomponent of the first component of complement, C1. The MRL/lpr/lpr mouse is an established model for SLE, developing both antinuclear and anti-type II collagen autoantibodies, and rheumatoid factors(s), exhibiting reduced complement levels and later on developing glomerulonephritis and often arthritis. We report here an age-dependent decrease in serum C1q levels coincident with the development of IgG2b autoantibodies reactive with mouse C1q in MRL/lpr/lpr mice. Unlike IgG2b, although high levels of IgM, Ig…

Systemic diseaseImmunologyArthritischemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesmedicine.disease_causeAutoimmunityMiceRheumatologyimmune system diseasesImmunology and AllergyMedicineAnimalsLupus Erythematosus Systemicskin and connective tissue diseasesAutoantibodiesLupus erythematosusbusiness.industryComplement C1qAutoantibodyGlomerulonephritismedicine.diseaseConnective tissue diseaseLupus NephritisDisease Models AnimalImmunologybusinessAnti-SSA/Ro autoantibodiesRheumatology international
researchProduct

Altered (oxidized) C1q induces a rheumatoid arthritis-like destructive and chronic inflammation in joint structures in arthritis-susceptible rats.

1997

Previous studies have identified an altered C1q molecule in synovial fluids from the joints of rheumatoid arthritis patients. We therefore immunized arthritis-susceptible Lewis 1A.AVN rats with either native C1q (C1q nat), altered (oxidized) C1q (C1q ox), or type II collagen (CII, induces arthritis in these animals), in order to induce arthritis. Unlike C1q nat, both CII and C1q ox were able to induce swelling and erythema of joints consistent with an arthritis-like inflammatory reaction. Histopathological evaluation of individual joint sections revealed synovitis, bursitis and tendovaginitis, massive joint destruction, and severe pannus formation. In a time-course study, no differences in …

musculoskeletal diseasesImmunologyType II collagenArthritischemical and pharmacologic phenomenaInflammationPathology and Forensic Medicinefluids and secretionsAntigenimmune system diseasesSynovitismedicineImmunology and AllergyAnimalsskin and connective tissue diseasesAutoimmune diseaseInflammationbiologybusiness.industryArthritisComplement C1qmedicine.diseaseRatsRats Inbred LewRheumatoid arthritisImmunologybiology.proteinFemaleJointsmedicine.symptomAntibodybusinessOxidation-ReductionClinical immunology and immunopathology
researchProduct

The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of pat…

1996

Cross-reactivity between type II collagen (CII) and C1q, the collagen-like subunit of the first component of complement, has been demonstrated in synovial fluid (SF) from rheumatoid arthritis (RA) patients. Many authors have studied autoimmunity to CII in RA, but little work has been done on autoimmunity to C1q in RA. In the data presented here, we have been able to show that in addition to native C1q, an altered form of C1q is present in SF from RA patients. Furthermore, a low molecular weight form of C1q is present in RA SF, although its role, if any, in the pathogenesis of RA is unclear. The presence in these RA SF of C1q-specific antibodies (IgG and IgM) has been studied and we have par…

ImmunologyMolecular Sequence DataType II collagenArthritischemical and pharmacologic phenomenamedicine.disease_causeurologic and male genital diseasesAutoimmunityArthritis Rheumatoidfluids and secretionsimmune system diseasesSynovial FluidmedicineImmunology and AllergySynovial fluidHumansAmino Acid Sequenceskin and connective tissue diseasesAutoantibodiesbiologybusiness.industryComplement C1qAutoantibodyAntibodies Monoclonalmedicine.diseaseComplement systemMolecular WeightRheumatoid arthritisImmunoglobulin GImmunologybiology.proteinCollagenAntibodybusinessResearch ArticleImmunology
researchProduct

Arthritis-regulating determinants on the collagen-like complement component C1q

1992

business.industryComplement component C1qImmunologyImmunologyMedicineArthritisbusinessmedicine.diseaseImmunology Today
researchProduct

Modulation of type II collagen-induced arthritis in DBA/1 mice by intravenous application of a peptide from the C1q-A chain.

1992

In this report we are able to show that intravenous (i.v.) application (day 0) of a nonapeptide (residues 26-34) from the human C1q A-chain (designated peptide A-C1q) prior to intradermal (i.d.) administration of chicken type II collagen (CII) in arthritis-susceptible DBA/1 mice (H2q), leads to abrogation of polymorphonuclear neutrophil (PMN) invasion into the joints. This nonapeptide exhibits epitope characteristics and high homology to residues 137-147 of CB11 (a cyanogen bromide fragment of chicken CII, known to contain both arthritis inducing and suppressing determinants). Arthritis index was lowest in animals pretreated i.v. with CII (as internal control), though animals pretreated i.v…

musculoskeletal diseasesMaleInjections IntradermalImmunologyMolecular Sequence DataType II collagenArthritischemical and pharmacologic phenomenaPeptideEpitopechemistry.chemical_compoundMiceAntigenAdjuvants ImmunologicmedicineImmunology and AllergyAnimalsAmino Acid Sequenceskin and connective tissue diseasesPeptide sequencechemistry.chemical_classificationbiologyArthritisComplement C1qHematologymedicine.diseaseMolecular biologyPeptide FragmentschemistryMice Inbred DBAImmunologyAntibody FormationInjections Intravenousbiology.proteinCyanogen bromideCollagenAntibodyOligopeptidesImmunobiology
researchProduct

Humoral autoreactivity directed against surfactant protein-A (SP-A) in rheumatoid arthritis synovial fluids.

2000

SUMMARY SP-A is found principally in the lung, and has been associated with lamellar bodies also found in the synovial joint. Both SP-A and C1q contain collagen-like regions, and SP-A and C1q have some structural similarities, both having a globular head region and a collagen-like tail. Here we are able to show that (i) autoreactivity to SP-A, as expressed by IgG and IgM autoantibodies, is present in synovial fluid (SF) isolated from patients with rheumatoid arthritis (RA); (ii) in absorption experiments only a limited degree of cross-reactivity between autoantibodies reactive with C1q and SP-A is observed; (iii) there is no cross-reactivity between autoantibodies reactive with type II coll…

Pulmonary Surfactant-Associated ProteinsKnee JointProteolipidsImmunologyType II collagenchemical and pharmacologic phenomenamedicine.disease_causeAutoantigensImmunoglobulin GAutoimmunityArthritis RheumatoidRheumatic DiseaseAntigenSynovial jointSynovial FluidmedicineImmunology and AllergySynovial fluidAnimalsHumansskin and connective tissue diseasesAutoantibodiesbiologyPulmonary Surfactant-Associated Protein AChemistryComplement C1qAutoantibodyPulmonary Surfactantsmedicine.anatomical_structureImmunoglobulin MImmunoglobulin MImmunoglobulin GImmunologybiology.proteinBinding Sites AntibodyCollagenPeptidesChickensDimerizationClinical and experimental immunology
researchProduct

Interleukin-7 or Interleukin-15 Enhances Survival ofMycobacterium tuberculosis-Infected Mice

2000

ABSTRACTBoth antigen-presenting cells and immune effector cells are required to effectively eradicate or containMycobacterium tuberculosis-infected cells. A variety of cytokines are involved to ensure productive “cross talk” between macrophages and T lymphocytes. For instance, infection of macrophages with mycobacteria leads to effective interleukin-7 (IL-7) and IL-15 secretion, and both cytokines are able to maintain strong cellular immune responses of α/β and γ/δ T cells. Here we show that either cytokine is able to enhance survival ofM. tuberculosis-infected BALB/c mice significantly compared to application of IL-2, IL-4, or phosphate-buffered saline (as a control). Enhanced survival cou…

Adoptive cell transfermedicine.medical_treatmentImmunologySpleenBiologyMicrobiologyMiceImmune systemmedicineAnimalsTuberculosisInterleukin-15Mice Inbred BALB CInterleukin-7InterleukinMycobacterium tuberculosisT lymphocyteAdoptive TransferDisease Models AnimalInfectious Diseasesmedicine.anatomical_structureCytokineInterleukin 15Microbial Immunity and VaccinesImmunologyCytokinesFemaleParasitologyTumor necrosis factor alphaSpleenInfection and Immunity
researchProduct

C1 Inhibitor-C1¯sComplexes Are Internalized and Degraded by the Low Density Lipoprotein Receptor-related Protein

1997

Like other serpin-enzyme complexes (SECs), proteinase-complexed C1 inhibitor (C1-INH) is rapidly cleared from the circulation and thought to be a neutrophil chemoattractant, suggesting that complex formation causes structural rearrangements exposing a domain which is recognized by specific cell surface receptors. However, the cellular receptor(s) responsible for the catabolism and potential mediation of chemotaxis by C1-INH-protease complexes remained obscure. To determine whether the SEC receptor mediates the binding and potential chemotaxis of C1-INH·C1s, we performed binding assays with HepG2 cells, neutrophils, and monocytes, and the results show that C1-INH·C1s neither bind to these ce…

chemistry.chemical_classificationCatabolismPeptideChemotaxisCell Biologybiochemical phenomena metabolism and nutritionrespiratory systemBiologybacterial infections and mycosesBiochemistryMolecular biologyrespiratory tract diseaseschemistry.chemical_compoundchemistryLow-density lipoproteinKnockout mouseLDL receptorheterocyclic compoundsAsialoglycoprotein receptorReceptorMolecular BiologyJournal of Biological Chemistry
researchProduct